Irofulven

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameIrofulven
Drug Alias NameIrofulveno伊罗夫文伊洛福芬Irofulven-1Irofulvenum +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsRNA polymerase II inhibitorsTopoisomerase II inhibitors
TargetsRNA polymerase IITopoisomerase II
Therapy Area/IndicationsSkin MelanomaCNS Embryonal TumorSolid tumours +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncology Venture A/S
China Registration ClassN/A

Develop Information

Active CompaniesLantern Pharma IncAllarity Therapeutics A/S
Inactive CompaniesUT Health San AntonioThe University Of ChicagoNational Cancer Institute +[6] 
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsSkin MelanomaCNS Embryonal TumorSolid tumours +[20] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG